Eric Ostertag, Poseida CEO
Takeda enlists Poseida in $3.6B+ nonviral gene therapy deal, though data remain years away from human studies
Takeda has been behind other major players in terms of cell and gene therapy development, but after announcing a collaboration with Selecta Biosciences last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.